振东制药推出第四期员工持股计划 金额上限2.5亿元

Core Viewpoint - Zhendong Pharmaceutical has completed the sale of its third employee stock ownership plan and announced the fourth plan, which aims to enhance employee engagement and align their interests with the company's growth [1][2]. Group 1: Employee Stock Ownership Plans - The third employee stock ownership plan has been fully sold off as of the announcement date, with the lock-up period ending on December 4, 2024 [1]. - The fourth employee stock ownership plan will cover up to 2,000 employees from the company and its subsidiaries, with a total funding cap of 250 million yuan, set at 1 yuan per share, totaling up to 250 million shares [1][2]. Group 2: Lock-up and Duration Rules - The fourth employee stock ownership plan will have a maximum duration of 36 months, starting from the date of the last stock transfer to the plan [2]. - The lock-up period for the stocks acquired under the fourth plan will last for 12 months from the date of the last purchase [2]. Group 3: Strategic Implications - The continuous rollout of employee stock ownership plans creates a positive cycle of "ending one plan and initiating another," effectively binding employee interests with corporate development [2]. - Zhendong Pharmaceutical is focusing on key sectors such as oncology, dermatology, and gynecology, with a stable core team expected to accelerate business implementation [2].